Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population

Journal of Crohn's and Colitis

Volumn 7, Issue 10, 2013, Pages

  Abreu, Cândida ^a,b   Magro, Fernando ^a,c,d   Santos Antunes, João ^a,c   Pilão, Artur ^e   Rodrigues Pinto, Eduardo ^a   Bernardes, José ^a   Bernardo, Alexandra ^a   Magina, Sofia ^a,c   Vilas Boas, Filipe ^a   Lopes, Susana ^a   Macedo, Guilherme ^a   Sarmento, António ^a,b  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e National Health Institute   (Portugal)

Author keywords

Anti TNF therapy; Latent tuberculosis screening; Tuberculosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; METHOTREXATE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACID FAST BACTERIUM; ADULT; AGE; AGED; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEX; TUBERCULOSIS;

ANTI-TNF-Α THERAPY; LATENT TUBERCULOSIS SCREENING; TUBERCULOSIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PORTUGAL; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884133830     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.004     Document Type: Article

References (29)

1. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-18894.
2. US Food and Drug administration Manufacturers of TNF blocker drugs must highlight risk of fungal infection 2008, U.S. F.D.A., Silver Spring, Maryland, [http://www.fda.gov/bbs/topics/NEWS/2008/NEWS01879.html, accessed in October 25th 2012].
3. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
4. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
5. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484.
6. Netea M.G., Radstake T., Joosten L.A., van der Meer J.W.M., Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003, 48:1853-1857.
7. Abreu C., Magro F., Vilas-Boas F., Lopes S., Macedo G., Sarmento A. Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature. J Crohns Colitis May 22 2012, [Epub ahead of print].
8. Ellerin T., Rubin R.H., Weinblatt M.E. Infections and anti tumor necrosis factor alpha therapy. Arthritis Rheum 2003, 48:3013-3022.
9. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
10. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
11. Nacci F., Matucci-Cerinic M. Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era. Best Pract Res Clin Rheumatol 2011, 25:375-388.
12. Fonseca Antunes A. Relatorio para o dia Mundial da Tuberculose Março 2011, Direcção Geral de Saúde, [In Portuguese].
13. Fonseca J.E., Lucas H., Canhão H., Duarte R., Santos M.J., Villar M., et al. Recomendações para diagnóstico e tratamento da tuberculose latente e activa nas doenças inflamatórias articulares candidatas a tratamento com fármacos inibidores do factor de necrose alfa. Acta Reumatol Port 2006, 31:237-245. [In Portuguese].
14. David H., Levy-Frebault V., Thorel M.F. Méthodes de laboratoire pour mycobactériologie clinique. Unite de la Tuberculose et des mycobactéries 1989, Institut Pasteur, Paris, [In French].
15. Gomez-Reino J.J., Carmona L., Rodríguez-Valverde V., Martín-Mola E., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003, 48:2122-2127.
16. Culver E.L., Travis S.P. How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets Feb 2010, 11(2):198-218.
17. Carmona L., Hernandez-Garcia C., Vadillo C., Pato E., Balsa A., González-Alvaro I., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003, 30:1436-1439.
18. Yamada T., Nakajima A., Inoue E., Tanaka E., Hara M., Tomatsu T., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006, 65:1661-1663.
19. Sichletidis L., Settas L., Spyratos D., Chloros D., Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006, 10:1127-1132.
20. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
21. Elizabeth C.H., Schluger N., Cush J., Chaisson R.E., Matteson E.L., Xu S., et al. Interferon-gamma release assay versus tuberculin skin test across RA, PsA, and AS patients prior to treatment with golimumab, a human anti-TNF antibody. Arthritis Rheum 2012, 64(7):2068-2077.
22. Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000, 49. [No. RR-6].
23. Klein N.C., Go C.H., Cunha B.A. Infections associated with steroids use. Infect Dis Clin North Am 2001, 15(2):423-432.
24. Kevin L., Winthrop S., Yamashita S., Beekmann E., Polgreen P.M. On behalf of the Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 2008, 46:1738-1740.
25. Garcia V.C., Rodriguez F.S., Martinez L.J., Salavert M., Vidal R., Carballeira M.R., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005, 40:756-759.
26. Belknap R., Reves R., Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005, 9:1057-1058.
27. Wallis R.S., Kyambadde P., Johnson J.L., Horter L., Kittle R., Pohle M., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004, 18:257-264.
28. Arend S.M., Leyten E.M.S., Franken W.P.J., Huisman E.M., Dissel J.T. A patient with de novo tuberculosis during anti-tumor necrosis factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007, 45:1470-1475.
29. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med Oct 11 2001, 345(15):1098-1104.